SCHEMBL21296915

SCHEMBL21296915

CCOC(=O)c1nn[nH]c1Sc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.47
TARBP2 Q15633 1/20 0.44
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 4/20 0.41
CYP19A1 P11511 1/20 0.41
ABCC1 P33527 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALOX15 P16050 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ELANE P08246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296903 0.87 MAPT (0.44) TARBP2KDM4EMAPTCYP19A1HTT
SCHEMBL21296967 0.86 NPC1 (0.48) TARBP2RAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL21296944 0.80 MAPT (0.56) RAB9AKDM4ENPC1MAPTCYP19A1
SCHEMBL29799115 0.80 MAPT (0.56) RAB9AKDM4ENPC1MAPTCYP19A1
SCHEMBL21296958 0.79 HAO1 (0.54) ALPLCYP2C9CYP2C19ALOX15
SCHEMBL23001880 0.78 CYP19A1 (0.43) KDM4EMAPTCYP19A1CYP1A2NPSR1
SCHEMBL29891693 0.78 CYP19A1 (0.43) KDM4EMAPTCYP19A1CYP1A2NPSR1
SCHEMBL21312773 0.76 HAO1 (0.50) ALPLRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL21296921 0.75 MAPT (0.52) ALPLTARBP2RAB9AKDM4ENPC1
SCHEMBL21296980 0.75 KDM4E (0.43) RAB9AKDM4ENPC1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX ALPL 576/4885TARBP2 4682/4885RAB9A 2533/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX ALPL 576/4885TARBP2 4682/4885RAB9A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.